logo-loader

Full interview: Acasti has 'put its finger on something very interesting' in new data, updates on TRILOGY trial

Published: 14:42 26 Nov 2019 EST

Acasti Pharma Inc (NASDAQ:ACST)(CVE:ACST) COO Pierre Lemieux tells Proactive the last patient completed their final visit in its TRILOGY 1 trial of lead drug CaPre, which treats severe hypertriglyceridemia. Lemieux says the Quebec-based company is on its way to reporting results by the end of the year. 

What's more, Lemieux talked about  how the company has 'put its finger on something very interesting' referencing recent pre-clinical data that indicates Acasti may be able to enter the diabetes space

Acasti Pharma outlines key benefits of recent Grace Therapeutics acquisition

Acasti Pharma Inc (TSX-V:ACST, NASDAQ:ACST). CEO Jan D’Alvise joined Proactive New York to discuss the Laval, Québec-based group's recent acquisition of Grace Therapeutics including its therapeutic pipeline consisting of three clinical stage and pre-clinical stage assets. D’Alvise walked...

on 8/10/21